Novo Nordisk (NVO) ended the recent trading session at $51.48, demonstrating a +1.82% change from the preceding day’s closing price. This change outpaced the S&P 500’s 0.51% loss on the day. On the other hand, the Dow registered a loss of 0.2%, and the technology-centric Nasdaq decreased by 1.47%. <\/p>\n
The drugmaker’s shares have seen an increase of 16.18% over the last month, surpassing the Medical sector’s gain of 3.63% and the S&P 500’s gain of 0.53%. <\/p>\n
The investment community will be closely monitoring the performance of Novo Nordisk in its forthcoming earnings report. The company’s upcoming EPS is projected at $0.82, signifying a 15.46% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $11.35 billion, reflecting a 2.89% fall from the equivalent quarter last year. <\/p>\n
For the full year, the Zacks Consensus Estimates project earnings of $3.38 per share and a revenue of $45.3 billion, demonstrating changes of -14.65% and -3.15%, respectively, from the preceding year. <\/p>\n
Investors might also notice recent changes to analyst estimates for Novo Nordisk. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. <\/p>\n
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. <\/p>\n
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.07% lower within the past month. Right now, Novo Nordisk possesses a Zacks Rank of #5 (Strong Sell). <\/p>\n
Looking at its valuation, Novo Nordisk is holding a Forward P\/E ratio of 14.95. This indicates a discount in contrast to its industry’s Forward P\/E of 16.37. <\/p>\n
It is also worth noting that NVO currently has a PEG ratio of 4.61. The PEG ratio is akin to the commonly utilized P\/E ratio, but this measure also incorporates the company’s anticipated earnings growth rate. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.6 as trading concluded yesterday. <\/p>\n
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 232, this industry ranks in the bottom 6% of all industries, numbering over 250. <\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk (NVO) ended the recent trading session at $51.48, demonstrating a +1.82% change from the preceding day’s…\n","protected":false},"author":2,"featured_media":131416,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[4862,272,13101,4861,1278],"class_list":["post-131415","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-medical-sector","tag-novo-nordisk","tag-pharmaceuticals-industry","tag-sp-500","tag-zacks-rank"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116939100278864098","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/131415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=131415"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/131415\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/131416"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=131415"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=131415"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=131415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}